Want to see HK:1643 full AI Analyst Report?
1643 Stock Chart & Stats
HK$0.51
<HK$0.01(1.54%)
At close: 4:00 PM EST
HK$0.51
<HK$0.01(1.54%)
Day’s Range― - ―
52-Week RangeHK$0.49 - HK$3.26
Previous CloseN/A
Volume456.00K
Average Volume (3M)639.13K
Market Cap
HK$583.20M
Enterprise ValueHK$583.30M
Total Cash (Recent Filing)HK$229.81M
Total Debt (Recent Filing)HK$69.03K
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding720,000,000
10 Day Avg. Volume382,100
30 Day Avg. Volume639,133
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.61
Price to Sales (P/S)2.14
P/FCF Ratio-18.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low debt and a strong equity base materially reduce solvency and refinancing risk. That financial flexibility supports sustaining operations during downturns, funding working capital or selective product investment, and enables strategic optionality without immediate external financing.
Demonstrated Cash Generation In Good YearsHistory of strong cash conversion in better years and positive operating cash flow in 2025 shows the operation can generate internal funds. This indicates the core manufacturing/distribution model can produce cash to reinvest or shore up liquidity when demand normalizes.
Prior Margin And Earnings PowerPast periods of robust margins imply the product mix, pricing or cost structure can deliver profitable outcomes. If demand or mix recovers, the firm has shown it can convert revenue into meaningful earnings, supporting medium-term return recovery without structural business redesign.
Bears Say
Steep Revenue DeclineA roughly 30% revenue contraction is a structural headwind that erodes scale, bargaining power, and fixed-cost absorption. Sustained top-line shrinkage risks long-term market share loss, weaker distributor relationships, and a slower recovery path for margins and cash generation.
Margin Compression And Swing To LossCompression of gross and net margins leading to a 2025 loss signals adverse demand, pricing pressure, or unfavorable mix. This negative operating leverage threatens sustainable profitability, may require structural cost cutting or repricing, and reduces the firm's ability to rebuild retained earnings.
Volatile And Negative Free Cash Flow RecentlyConsecutive years of negative free cash flow constrain reinvestment, limit buffer for shocks, and increase reliance on balance sheet reserves. Persistent FCF volatility raises execution risk for product launches or commercialization and could force trade-offs in capex, R&D, or working capital.
Modern Chinese Medicine Group Co. Ltd. News
1643 FAQ
What was Modern Chinese Medicine Group Co. Ltd.’s price range in the past 12 months?
Modern Chinese Medicine Group Co. Ltd. lowest stock price was HK$0.48 and its highest was HK$3.26 in the past 12 months.
What is Modern Chinese Medicine Group Co. Ltd.’s market cap?
Modern Chinese Medicine Group Co. Ltd.’s market cap is HK$583.20M.
When is Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date?
Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 29 days.
How were Modern Chinese Medicine Group Co. Ltd.’s earnings last quarter?
Modern Chinese Medicine Group Co. Ltd. released its earnings results on Mar 30, 2026. The company reported -HK$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.027.
Is Modern Chinese Medicine Group Co. Ltd. overvalued?
According to Wall Street analysts Modern Chinese Medicine Group Co. Ltd.’s price is currently Overvalued.
Does Modern Chinese Medicine Group Co. Ltd. pay dividends?
Modern Chinese Medicine Group Co. Ltd. pays a Notavailable dividend of HK$0.017 which represents an annual dividend yield of N/A. See more information on Modern Chinese Medicine Group Co. Ltd. dividends here
What is Modern Chinese Medicine Group Co. Ltd.’s EPS estimate?
Modern Chinese Medicine Group Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modern Chinese Medicine Group Co. Ltd. have?
Modern Chinese Medicine Group Co. Ltd. has 720,000,000 shares outstanding.
What happened to Modern Chinese Medicine Group Co. Ltd.’s price movement after its last earnings report?
Modern Chinese Medicine Group Co. Ltd. reported an EPS of -HK$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.013%.
Which hedge fund is a major shareholder of Modern Chinese Medicine Group Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1643
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Modern Chinese Medicine Group Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.26%
Trailing 12-Months
Company Description
Modern Chinese Medicine Group Co. Ltd.
As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. Its extensive product line provides treatments for a wide array of health issues, including qi deficiency, blood stasis, cardiovascular and cerebrovascular conditions, digestive and gastrointestinal ailments, gynecological problems, as well as disorders affecting the respiratory and nervous systems. Established in 1986, the enterprise maintains its principal offices in Chengde, China, and operates as a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
Technical Analysis
Tong Ren Tang Technologies Co
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―